Overview Dividends

(NTLA) Intellia Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US45826J1051

In-Vivo CRISPR, CAR-T, NK Cell Therapy, Gene Editing

EPS (Earnings per Share)

EPS (Earnings per Share) of NTLA over the last years for every Quarter: "2020-09": -0.47, "2020-12": -0.69, "2021-03": -0.69, "2021-06": -1.01, "2021-09": -0.97, "2021-12": -1.09, "2022-03": -1.96, "2022-06": -1.33, "2022-09": -1.49, "2022-12": -1.4, "2023-03": -1.17, "2023-06": -1.4, "2023-09": -1.38, "2023-12": -1.46, "2024-03": -1.12, "2024-06": -1.52, "2024-09": -1.34, "2024-12": -1.27, "2025-03": -1.1, "2025-06": -0.98, "2025-09": -0.92,
EPS Growth (3y CAGR): 47.58%
EPS Trend (3y Corr): 63.6%
Last SUE: 0.56σ
Qual. Beats: 0

Revenue

Revenue of NTLA over the last years for every Quarter: 2020-09: 22.22, 2020-12: 6.595, 2021-03: 6.445, 2021-06: 6.55, 2021-09: 7.204, 2021-12: 12.854, 2022-03: 11.252, 2022-06: 14.03, 2022-09: 13.266, 2022-12: 13.573, 2023-03: 12.606, 2023-06: 13.594, 2023-09: 11.992, 2023-12: -1.917, 2024-03: 28.935, 2024-06: 6.957, 2024-09: 9.111, 2024-12: 12.874, 2025-03: 16.627, 2025-06: 14.245, 2025-09: 13.782,
Revenue Growth (3y CAGR): 0.56%
Revenue Trend (3y Corr): 13.2%
Last SUE: -0.03σ
Qual. Beats: 0
Risk via 10d forecast
Volatility 179%
Value at Risk 5%th 270%
Relative Tail Risk -8.18%
Reward TTM
Sharpe Ratio -0.07
Alpha -64.77
Character TTM
Hurst Exponent 0.459
Beta 1.532
Beta Downside 1.310
Drawdowns 3y
Max DD 87.80%
Mean DD 51.97%
Median DD 51.71%

Description: NTLA Intellia Therapeutics November 17, 2025

Intellia Therapeutics (NASDAQ: NTLA) is a Cambridge-based, clinical-stage biotech that develops curative in-vivo genome-editing therapies using its CRISPR-Cas9 platform. Its lead programs are NTLA-2001 (Phase 1 for transthyretin amyloidosis) and NTLA-2002 (Phase 1/2 for hereditary angioedema). The firm also pursues engineered cell-therapy assets, partnering with AvenCell (universal CAR-T), Kyverna (allogeneic CD19 CAR-T for autoimmune disease), ONK Therapeutics (engineered NK cells) and ReCode (genomic medicines for cystic fibrosis). Intellia was founded in 2014 and operates under multiple exclusive license agreements to expand its pipeline.

Key metrics as of the latest filing: market capitalization ≈ $5 billion, cash and equivalents of roughly $600 million giving a runway of about 12-18 months at current burn rate, and a Q2-2024 net loss of $115 million driven by R&D spend. The CRISPR-based therapeutics market is projected to grow at a CAGR > 30 % through 2030, while early-stage data from NTLA-2001 showed > 50 % reduction in serum transthyretin levels after a single dose, suggesting strong proof-of-concept momentum.

For a deeper, data-driven assessment of NTLA’s valuation assumptions and scenario analysis, you may find the analytical tools on ValueRay worth exploring.

NTLA Stock Overview

Market Cap in USD 1,008m
Sub-Industry Biotechnology
IPO / Inception 2016-05-06
Return 12m vs S&P 500 -47.8%
Analyst Rating 4.34 of 5

NTLA Dividends

Currently no dividends paid

NTLA Growth Ratios

Metric Value
CAGR 3y -44.35%
CAGR/Max DD Calmar Ratio -0.51
CAGR/Mean DD Pain Ratio -0.85
Current Volume 6091.1k
Average Volume 7555k

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-445.8m TTM) > 0 and > 6% of Revenue (6% = 3.45m TTM)
FCFTA -0.45 (>2.0%) and ΔFCFTA -13.65pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 848.7% (prev 1405 %; Δ -556.0pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.44 (>3.0%) and CFO -410.6m > Net Income -445.8m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 6.21 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (110.2m) change vs 12m ago 9.09% (target <= -2.0% for YES)
Gross Margin -41.70% (prev 76.36%; Δ -118.1pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 5.48% (prev 3.67%; Δ 1.81pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -20.58 (EBITDA TTM -456.1m / Interest Expense TTM -22.8m) >= 6 (WARN >= 3)

Altman Z'' -23.13

(A) 0.53 = (Total Current Assets 581.9m - Total Current Liabilities 93.7m) / Total Assets 925.3m
(B) -2.70 = Retained Earnings (Balance) -2.49b / Total Assets 925.3m
warn (B) unusual magnitude: -2.70 — check mapping/units
(C) -0.45 = EBIT TTM -468.6m / Avg Total Assets 1.05b
(D) -14.10 = Book Value of Equity -2.49b / Total Liabilities 176.9m
Total Rating: -23.13 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 34.12

1. Piotroski 0.0pt = -5.0
2. FCF Yield -69.39% = -5.0
3. FCF Margin data missing
4. Debt/Equity 0.13 = 2.49
5. Debt/Ebitda 0.21 = 2.47
6. ROIC - WACC (= -58.78)% = -12.50
7. RoE -57.24% = -2.50
8. Rev. Trend 13.16% = 0.99
9. EPS Trend 63.59% = 3.18

What is the price of NTLA shares?

As of November 19, 2025, the stock is trading at USD 8.48 with a total of 6,091,083 shares traded.
Over the past week, the price has changed by -12.85%, over one month by -65.74%, over three months by -20.97% and over the past year by -40.16%.

Is NTLA a buy, sell or hold?

Intellia Therapeutics has received a consensus analysts rating of 4.34. Therefore, it is recommended to buy NTLA.
  • Strong Buy: 18
  • Buy: 4
  • Hold: 6
  • Sell: 1
  • Strong Sell: 0

What are the forecasts/targets for the NTLA price?

Issuer Target Up/Down from current
Wallstreet Target Price 22.9 170.4%
Analysts Target Price 22.9 170.4%
ValueRay Target Price 5.6 -34.2%

NTLA Fundamental Data Overview November 16, 2025

Market Cap USD = 1.01b (1.01b USD * 1.0 USD.USD)
P/S = 17.517
P/B = 1.3465
P/EG = -0.0969
Beta = 2.11
Revenue TTM = 57.5m USD
EBIT TTM = -468.6m USD
EBITDA TTM = -456.1m USD
Long Term Debt = 98.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 27.4m USD (from shortTermDebt, last quarter)
Debt = 98.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -95.4m USD (from netDebt column, last quarter)
Enterprise Value = 594.6m USD (1.01b + Debt 98.0m - CCE 511.0m)
Interest Coverage Ratio = -20.58 (Ebit TTM -468.6m / Interest Expense TTM -22.8m)
FCF Yield = -69.39% (FCF TTM -412.6m / Enterprise Value 594.6m)
FCF Margin = -717.3% (FCF TTM -412.6m / Revenue TTM 57.5m)
Net Margin = -774.9% (Net Income TTM -445.8m / Revenue TTM 57.5m)
Gross Margin = -41.70% ((Revenue TTM 57.5m - Cost of Revenue TTM 81.5m) / Revenue TTM)
Gross Margin QoQ = -472.8% (prev 100.0%)
Tobins Q-Ratio = 0.64 (Enterprise Value 594.6m / Total Assets 925.3m)
Interest Expense / Debt = 9.02% (Interest Expense 8.83m / Debt 98.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = -370.2m (EBIT -468.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.21 (Total Current Assets 581.9m / Total Current Liabilities 93.7m)
Debt / Equity = 0.13 (Debt 98.0m / totalStockholderEquity, last quarter 748.4m)
Debt / EBITDA = 0.21 (negative EBITDA) (Net Debt -95.4m / EBITDA -456.1m)
Debt / FCF = 0.23 (negative FCF - burning cash) (Net Debt -95.4m / FCF TTM -412.6m)
Total Stockholder Equity = 778.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -48.18% (Net Income -445.8m / Total Assets 925.3m)
RoE = -57.24% (Net Income TTM -445.8m / Total Stockholder Equity 778.9m)
RoCE = -53.44% (EBIT -468.6m / Capital Employed (Equity 778.9m + L.T.Debt 98.0m))
RoIC = -47.53% (negative operating profit) (NOPAT -370.2m / Invested Capital 778.9m)
WACC = 11.26% (E(1.01b)/V(1.11b) * Re(11.66%) + D(98.0m)/V(1.11b) * Rd(9.02%) * (1-Tc(0.21)))
Discount Rate = 11.66% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 13.39%
Fair Price DCF = unknown (Cash Flow -412.6m)
EPS Correlation: 63.59 | EPS CAGR: 47.58% | SUE: 0.56 | # QB: 0
Revenue Correlation: 13.16 | Revenue CAGR: 0.56% | SUE: -0.03 | # QB: 0

Additional Sources for NTLA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle